UroMems

Executive Summary

UroMems is a French medical device company developing UroActive®, the world's first smart, active implant for stress urinary incontinence (SUI). SUI affects millions of women and men worldwide, with current solutions like slings or manual artificial urinary sphincters offering limited efficacy, invasiveness, or adjustability. UroActive leverages microelectromechanical systems (MEMS) to create an automated, remotely adjustable implant that dynamically responds to patient needs, aiming to improve outcomes and quality of life. The device is designed to be implanted via a minimally invasive procedure and can be fine-tuned non-invasively post-surgery, addressing a key unmet need in urology. Founded in 2011, UroMems operates from Grenoble, France, and Minneapolis, Minnesota. The company has raised significant funding but remains private and pre-commercial. UroActive is currently in clinical development, with pivotal trials expected to read out soon. If successful, the device could disrupt the SUI treatment market, estimated at over $1 billion. Key risks include regulatory hurdles and competition from established urology device makers. However, the technology's unique value proposition positions UroMems as a promising player in smart implantables.

Upcoming Catalysts (preview)

• Q3 2026Pivotal clinical trial results for UroActive70% success
• Q4 2026CE Mark approval application or submission60% success
• H2 2026Strategic partnership or Series C financing round75% success